Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoGAA versus alglucosidase alfa in treatment-naive late-onset Pompe disease
NL-OMON46174Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pompe disease comparing NeoGAA with Alglucosidase alfa (2 arms). Primary endpoint: Change in upright forced vital capacity percent predicted. Started May 2017; status: completed.
02
Drugs
avalglucosidase alfaalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON46174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46174.